Avanir Pharma Submits European Marketing Authorization Application For Nuedexta

California based Avanir Pharmaceuticals submitted an application to the European Medicines Agency (EMA) to market Nuedexta for the treatment of pseudobulbar affect (PBA). Nuedexta was approved by the U.S. Food and Drug Administration in October 2010 for PBA, a neurologic condition that is characterized by frequent outbursts of involuntary crying or laughing. PBA occurs in ALS, multiple sclerosis, and other neurological conditions.

Click here to read more.

Share this: